GeneralConnection.com ➔ Dictionary
Dictionary Search

degrader

Synonyms

Noun

1. debaser

2. person, individual, someone, somebody, mortal, human, soul

Usage
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca - PR Newswire
When ADCs meet targeted protein degraders: The emerging field of degrader-antibody conjugates - Labiotech.eu
AstraZeneca plucks EGFR degrader from Pinetree for $25M - Fierce Biotech
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia - Nature
First-in-Class Investigational Drug KRAS G12D Degrader Shows Promise in Lung and Pancreatic Cancers - Memorial Sloan Kettering Cancer Center
Genexine’s First-in-Class SOX2 Degrader GX-BP1 Demonstrates Up to 96% TGI and Eliminates Tumor Regrowth in Preclinical Models - Business Wire
Nurix pushes its degrader forward | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
AstraZeneca takes global rights to an EGFR cancer drug in $25M deal - Stock Titan
A decade of trust looking into the future of new modalities - Roche
A targeted protein degrader that doubles as a cancer vaccine - C&EN
Roche and C4 Therapeutics to advance degrader-antibody conjugates research - Pharmaceutical Technology
Roche Explores Degrader Antibody Conjugates To Support Oncology Pipeline - Yahoo Finance
PineTree Therapeutics Secures $25 Million from AstraZeneca Option on EGFR Degrader PTX-299 - TipRanks
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models - Nature
Astellas makes its KRAS degrader choice | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Development of a targeted BioPROTAC degrader selective for misfolded SOD1 - Nature
Astellas takes its G12D degrader pivotal | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries - Nature
Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening - Nature
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2 - Nature
A new clinical KRAS degrader | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Updated Efficacy and Safety Results of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the Ongoing Phase 1 CaDAnCe-101 Study - OncLive
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity - Wiley
Phase 1/2 trial launches of molecular glue degrader for ccRCC - Urology Times
Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline - Fierce Biotech
Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program - Fierce Biotech
Discovery of KRAS(G12D) selective degrader ASP3082 - Nature
Roche flunks its first-line degrader test | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Google, Johnson & Johnson back protein degrader start-up - C&EN
BeOne looks to a degrader combo | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model - Nature
ASCO-GI – Astellas focuses on a degrader-chemo combo | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity - Nature
Developing a CITK protein degrader using the QuicTPD™ platform - Chemistry World
Orum pulls in $100M to fund degrader-antibody conjugate pipeline - FirstWord Pharma
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha - Nature
ASH 2025 preview – another degrader fight | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Arvinas and Pfizer seek a new home for protein degrader drug - Chemistry World
Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic - Fierce Biotech
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia - Science | AAAS
Transcriptomic and epigenetic profiling of neuroblastoma states in response to RBM39 degrader - Nature
First Volunteer Dosed in Innocare’s New VAV1 Degrader Trial - The Clinical Trial Vanguard
Degrader Therapy Tests Efficacy Against Advanced Prostate Cancer in Preclinical Studies - Jie Luo - UroToday
C4 Therapeutics, Roche partner on cancer degrader conjugates - Investing.com
Nurix trims workforce as pivotal trial for lead BTK degrader kicks off - Fierce Biotech
No differentiation for Roche's degrader | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1 - Nature
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference - Yahoo Finance
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected - Yahoo Finance
Capturing degrader efficacy through live-cell kinetics - Drug Discovery News
PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader - PR Newswire
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial - PR Newswire
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide (NASDAQ:NRIX) - Seeking Alpha
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China - Yahoo Finance
Astellas and Amgen join the pan-KRAS push | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
6 Biotechs Targeting the Undruggable with Precision - Clarivate
NEK7 Degrader MRT-8102 Shows Promise in Preclinical Data - The Clinical Trial Vanguard
PD-L1 degraders emerge | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology - PR Newswire
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program - Yahoo Finance
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 - Yahoo Finance
BeOne tries to repeat the inhibitor-degrader double | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader - Dermatology Times
Former Genentech leaders’ protein degrader startup nets $107M - Endpoints News
Innocare’s VAV1 degrader ICP-538 cleared for clinic in China - BioWorld News
Accelerating protein degrader discovery with the direct-to-biology workflow - News-Medical
EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline - Pulse 2.0
Kazia advances nuclear PD-L1 degrader with pre-clinical data - The Pharma Letter
Triple meeting 2025 – Astellas touts a degrader turnaround | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
BeOne Medicines’ BTK degrader gains EMA PRIME designation - Pharmaceutical Technology
Innocare IND Approval For New VAV1 Degrader Trial In China - The Clinical Trial Vanguard
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Yahoo Finance
First-in-Class KRAS-Degrader Promising in Pancreatic, Lung Cancers - MedPage Today
High-throughput proteomics is identifying molecular glue degraders at scale - Nature
Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026 - BioSpace
Novel BTK Degrader Shows Activity in CLL/SLL Regardless of Mutation Status - CancerNetwork
Discovery of an LSD1 PROTAC degrader - PNAS
Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader - GlobeNewswire
Wungki Park Presents Setidegrasib, the KRAS Degrader in Phase 1 Trial for Pancreatic and Lung Cancers - Oncodaily
ICR Centre for Protein Degradation and NEOsphere Biotechnologies announce research collaboration to discover new molecular glue degrader therapeutics - The Institute of Cancer Research (ICR)
ASH 2025 – BeOne pulls away from Nurix | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting - The Manila Times
Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases - Business Wire
Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera - BioSpace
Novartis agrees $5.7bn degrader deal with Monte Rosa - pharmaphorum
Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors - Stock Titan
Kymera snags Gilead as new partner, while Sanofi opts for next-gen IRAK4 degrader - FirstWord Pharma
Months after layoffs, AbbVie-partnered protein degrader specialist Plexium raises $60M - Fierce Biotech
FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156 - GlobeNewswire
Sanofi pays $15M for another STAT6 degrader from fruitful Nurix collab - Fierce Biotech
From undruggable to oral therapy: The rise of STAT6 degraders - Labiotech.eu
30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial - CancerNetwork
Solid-Phase Parallel Synthesis of Photocleavable Bifunctional Molecules Enables Efficient Phenotypic Protein Degrader Discovery - Wiley Online Library
Kymera stock jumps on first clinical data for oral STAT6 degrader - FirstWord Pharma
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class - PR Newswire
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC - Seeking Alpha
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs - Business Wire
A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells | Leukemia - Nature
Foreign Language Equivalents
Foreign Language Equivalents of 'degrader'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
degarder,   deggrader,   degradr,   degader,   degtader,   edgrader,   segrader,   dgrader,   degradet,   degradre,   dergader,   degrrader,   ddegrader,   fegrader,   degrdaer,   degradee,   degradwr,   degraderr,   dgerader,   degradder,   degrafer,   degradrr,   degeader,   deegrader,   degraser,   degrder,   degrsder,   derader,   drgrader,   egrader,   dehrader,   defrader,   degradeer,   degrador,   degraader,   degraer,   dwgrader,   degrade,   degraedr
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z